CN103739680A - Polypeptides capable of inhibiting focal adhesion kinase and application thereof - Google Patents
Polypeptides capable of inhibiting focal adhesion kinase and application thereof Download PDFInfo
- Publication number
- CN103739680A CN103739680A CN201310748503.2A CN201310748503A CN103739680A CN 103739680 A CN103739680 A CN 103739680A CN 201310748503 A CN201310748503 A CN 201310748503A CN 103739680 A CN103739680 A CN 103739680A
- Authority
- CN
- China
- Prior art keywords
- focal adhesion
- kinase
- adhesion kinase
- cell
- adhesion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 24
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 22
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 22
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 title abstract description 13
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 title abstract description 13
- 230000002401 inhibitory effect Effects 0.000 title abstract description 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 7
- 108091000080 Phosphotransferase Proteins 0.000 claims description 20
- 102000020233 phosphotransferase Human genes 0.000 claims description 20
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 14
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- 230000004083 survival effect Effects 0.000 abstract description 9
- 241000699670 Mus sp. Species 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract description 2
- 239000002547 new drug Substances 0.000 abstract description 2
- 101000878536 Homo sapiens Focal adhesion kinase 1 Proteins 0.000 description 13
- 102100037813 Focal adhesion kinase 1 Human genes 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000013016 damping Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 6
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 6
- 229940111980 Focal adhesion kinase inhibitor Drugs 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 229940124783 FAK inhibitor Drugs 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 229960004528 vincristine Drugs 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000001650 focal adhesion Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DTGKSKDOIYIVQL-NQMVMOMDSA-N (+)-Borneol Natural products C1C[C@]2(C)[C@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-NQMVMOMDSA-N 0.000 description 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- ZIWWTZWAKYBUOB-CIUDSAMLSA-N Ala-Asp-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O ZIWWTZWAKYBUOB-CIUDSAMLSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 240000005636 Dryobalanops aromatica Species 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 description 1
- NKRJALPCDNXULF-BYULHYEWSA-N Ile-Asp-Gly Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O NKRJALPCDNXULF-BYULHYEWSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- DOBIBIXIHJKVJF-XKBZYTNZSA-N Thr-Ser-Gln Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(N)=O DOBIBIXIHJKVJF-XKBZYTNZSA-N 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- ADBDQGBDNUTRDB-ULQDDVLXSA-N Tyr-Arg-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O ADBDQGBDNUTRDB-ULQDDVLXSA-N 0.000 description 1
- UDNYEPLJTRDMEJ-RCOVLWMOSA-N Val-Asn-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)O)N UDNYEPLJTRDMEJ-RCOVLWMOSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 102000057090 human PTK2 Human genes 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000029115 microtubule polymerization Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310748503.2A CN103739680B (en) | 2013-12-31 | 2013-12-31 | A kind of anti-adhesion spot kinase polypeptide and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310748503.2A CN103739680B (en) | 2013-12-31 | 2013-12-31 | A kind of anti-adhesion spot kinase polypeptide and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103739680A true CN103739680A (en) | 2014-04-23 |
CN103739680B CN103739680B (en) | 2016-03-30 |
Family
ID=50496764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310748503.2A Expired - Fee Related CN103739680B (en) | 2013-12-31 | 2013-12-31 | A kind of anti-adhesion spot kinase polypeptide and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103739680B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103739678A (en) * | 2013-12-31 | 2014-04-23 | 罗瑞雪 | Polypeptides capable of inhibiting focal adhesion kinase and application thereof |
CN103923187A (en) * | 2014-01-17 | 2014-07-16 | 南通诚信氨基酸有限公司 | Focal adhesion kinase inhibitor polypeptide and its application |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101801401A (en) * | 2007-03-16 | 2010-08-11 | 佛罗里达大学研究基金会 | Kinase protein binding inhibitors |
CN102648197A (en) * | 2009-08-12 | 2012-08-22 | 铂雅制药公司 | Method of promoting apoptosis and inhibiting metastasis |
-
2013
- 2013-12-31 CN CN201310748503.2A patent/CN103739680B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101801401A (en) * | 2007-03-16 | 2010-08-11 | 佛罗里达大学研究基金会 | Kinase protein binding inhibitors |
CN102648197A (en) * | 2009-08-12 | 2012-08-22 | 铂雅制药公司 | Method of promoting apoptosis and inhibiting metastasis |
Non-Patent Citations (3)
Title |
---|
HUNGERFORD,J.E等: "Inhibitioin of pp125FAK in Cultured Fibroblasts Results in Apoptosis", 《JOURNAL OF CELL BIOLOGY》, vol. 135, no. 5, 1 December 1996 (1996-12-01), pages 1383 - 1390 * |
张文静等: "局部黏着斑激酶作为肿瘤治疗靶点的研究进展", 《生命科学》, vol. 23, no. 1, 31 January 2011 (2011-01-31), pages 7 - 12 * |
许吕宏等: "黏着斑激酶基因沉默靶向治疗白血病的实验研究", 《中国实验血液学杂志》, vol. 19, no. 3, 31 December 2011 (2011-12-31), pages 602 - 606 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103739678A (en) * | 2013-12-31 | 2014-04-23 | 罗瑞雪 | Polypeptides capable of inhibiting focal adhesion kinase and application thereof |
CN103923187A (en) * | 2014-01-17 | 2014-07-16 | 南通诚信氨基酸有限公司 | Focal adhesion kinase inhibitor polypeptide and its application |
Also Published As
Publication number | Publication date |
---|---|
CN103739680B (en) | 2016-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | The emerging role of CaMKII in cancer | |
Noberini et al. | Targeting Eph receptors with peptides and small molecules: progress and challenges | |
Tang et al. | Paclitaxel nanoparticle awakens immune system to fight against cancer | |
CN103923184A (en) | Focal adhesion kinase inhibitor polypeptide and its application | |
CN103739680A (en) | Polypeptides capable of inhibiting focal adhesion kinase and application thereof | |
Zhang et al. | Targeting death-associated protein kinases for treatment of human diseases: recent advances and future directions | |
CN103923187A (en) | Focal adhesion kinase inhibitor polypeptide and its application | |
Yang et al. | Inhibition effects of 7-phloro-eckol from Ecklonia cava on metastasis and angiogenesis induced by hypoxia through regulation of AKT/mTOR and ERK signaling pathways | |
CN103739678B (en) | Anti-adhesion spot kinase polypeptide and application thereof | |
CN103923179A (en) | Focal adhesion kinase inhibitor polypeptide and its application | |
CN103819554A (en) | Synthetic SP series polypeptides and application thereof | |
CN103254287A (en) | Tubulin depolymerizing agent polypeptides and application thereof | |
CN105585618A (en) | Focal adhesion kinase inhibitor polypeptide and application thereof | |
Viana et al. | Targeting the heat shock response induced by modulated electro-hyperthermia (mEHT) in cancer | |
CN103265621B (en) | Tubulin depolymerizing agent polypeptide and application thereof | |
CN103254281B (en) | Tubulin polymerizing agent polypeptides 6 and application thereof | |
CN103288926B (en) | Tubulin polymerization agent polypeptide and application thereof | |
CN103254282B (en) | Tubulin depolymerizing agent polypeptides 5 and application thereof | |
CN103254284B (en) | Tubulin depolymerizing agent polypeptides and application thereof | |
CN103254289B (en) | Tubulin depolymerizing agent polypeptides and application thereof | |
CN103254283B (en) | Tubulin polymerizing agent polypeptides and application thereof | |
CN104693280A (en) | Signal-transducer-and-activator-of-transcription suppressing polypeptide and application thereof | |
CN104693289A (en) | Tight-junction protein inhibitor polypeptide and application thereof | |
CN104031128A (en) | Interleukin-33 inhibitor polypeptide and application thereof | |
CN103304633A (en) | Tubulin polymerizing agent polypeptides 1 and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Xu Yongjun Inventor before: Luo Ruixue |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160303 Address after: 314000, room 8, building 778, 1205 Asia Pacific Road, Nanhu District, Jiaxing, Zhejiang, Jiaxing Applicant after: Yuan Tai bio tech ltd, Zhejiang Address before: 639 No. 211198 Jiangsu province Nanjing city Jiangning District University City longmian Road Applicant before: Luo Ruixue |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160330 Termination date: 20171231 |